x
 
  • Jun 01 ,2023

    BETHESDA, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will present at the Jefferies Healthcare Conference, taking place June 7-9 in New York, NY. Jefferies Healthcare ConferenceDate: Wednesday, June 7, 2023 Time: 4:30 PM ET Format: Corporate Presentation Webcast:...

    Read More >

  • May 12 ,2023

    Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for start of Phase 1 clinical trial of GT-02287 to the Human Research Ethics Committee (HREC) in Australia in mid-2023Received a $2.8 million (CHF $2.5 million) grant from Innosuisse, the Swiss Innovation Agency, to advance the development of GT-02287 in GBA1 Parkinson’s diseaseObtained a grant in the aggregate amount of $1.3 million (EUR 1.2 million) to...

    Read More >

  • May 03 ,2023

    BETHESDA, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Innosuisse, the Swiss Innovation Agency, supports GT Gain Therapeutics SA with the amount of CHF 2.5 million (~$2.8 million) to develop GT-02287, Gain’s lead program for GBA1 Parkinson’s disease. The Company’s Swiss Accelerator innovation project supported by Innosuisse entitled...

    Read More >

 

MORE